FOXP3 and malignant colon neoplasm: More importantly, in CT26 colon cancer–bearing mice, the combinational use of imiquimod (TLR7) with autologous GVAX therapy displayed increased expression levels of DC marker CD86 and CD9, which led to decreased Foxp3+ regulatory T cells in TDLNs and increased CD8+ T cells which correlate with an antitumor phenotype (36).